drugset / Trial / NCT03192527

Single Dose Recombinant Human Follicle Stimulating Hormone Fc Husion Protein (KN015) in Healthy Volunteers

NCT03192527

Phase 1 Unknown 50 enrolled Alphamab Jilin Co., Ltd.
RandomizedParallel-groupDouble-blindBasic science

Summary

KN015,the active substance recombinant human Follicle Stimulating Hormone(FSH) Fc fusion protein, which belongs to the pharmaceutical class gonadotropins.KN015 is proposed for Assisted Reproductive Technology (ART) programs only. Its indication is Controlled Ovarian Stimulation (COS)in combination with a gonadotropin releasing hormone (GnRH) antagonist for the development of multiple follicles in women participating in an ART program. Due to its prolonged duration of FSH activity compared to conventional recombinant FSH (rFSH), a single subcutaneous injection of the recommended dose of KN015 may replace any daily rFSH preparation in a COS treatment cycle. This study is to evaluation of the safety, tolerability, pharmacokinetics and pharmacodynamics of KN015 in healthy Chinese female subjects.

Timeline

Start
2017-06
Primary completion
2019-03
Completion
2019-06

Drugs

EvaluationDrugModalityDoseRoute
Subject KN015 Protein / enzyme biologic 20 ug Subcutaneous
Subject KN015 Protein / enzyme biologic 40 ug Subcutaneous
Subject KN015 Protein / enzyme biologic 60 ug Subcutaneous
Background Triptorelin Other / unclassified

Indications